Pharsight

Drugs that contain Ombitasvir; Paritaprevir; Ritonavir

1. Technivie patents expiration

TECHNIVIE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(5 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(7 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(5 months from now)

US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(5 months from now)

US8399015

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form
Feb, 2025

(11 months from now)

US8268349

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form
Feb, 2025

(11 months from now)

US9006387 ABBVIE INC Anti-viral compounds
Jun, 2030

(6 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV
Apr, 2031

(7 years from now)

US8686026 ABBVIE INC Solid compositions
Jun, 2031

(7 years from now)

US8420596

(Pediatric)

ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Oct, 2031

(7 years from now)

Market Authorisation Date: 24 July, 2015

Treatment: Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir

Dosage: TABLET;ORAL

More Information on Dosage

TECHNIVIE family patents

Family Patents